PMC8660592_01
(A) Time course of clinical parameters in this subject. On admission, we started insulin therapy. About 3 months later, we stopped insulin therapy and changed to 50 mg of sitagliptin. His good glycemic control continued, although his anti-GAD antibody and anti-IA-2 antibody titers were very high for over 4 years. HOMA-beta showed his beta-cell function was retained, although it was decreased. (B) Seventy-five grams of oral glucose tolerance test in this subject 4 years after being diagnosed of T1DM. His insulin secretory capacity was preserved, although it was decreased. HbA1c, hemoglobin A1c; HOMA-beta, homeostatic model of assessment-beta; GAD, glutamic acid decarboxylase; IA-2, insulinoma-associated protein-2.
fimmu-12-752423-g001.jpg
PMC8660592_01_fimmu-12-752423-g001.jpg
f1
Nonetheless, interestingly, his glycemic control was continuously very good and HbA1c levels were about 6% for over 4 years with sitagliptin therapy alone ( Figure 1A ). As shown in  Figure 1B , his GSIS was preserved, although it was decreased.